And elevated CSGALNACT2 expression had longer survival outcomes in ovarian cancer patients with Paclitaxel or Docetaxel treatment by Kaplan–Meier survival analysis (Fig. 1H, Supplementary Fig. 1B and C). Here, CSGALNACT2 is linked to ovarian cancer.